HANSEN-TECHNOLOGIES
25.4.2024 12:01:33 CEST | Business Wire | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water, and communications industries, is pleased to announce that Stockholm Exergi, a major energy provider in Sweden, is the latest to join the growing community of Hansen Trade users. Enabled by Hansen Trade, Stockholm Exergi will commence operations in a balance responsible party role and leverage the platform to process all trading operations in physical power markets, including Day-Ahead, Intraday, and Ancillary Services market trading.
Hansen Trade enables Stockholm Exergi to participate in all marketplaces with an automated trading tool, with a modern, cloud-native, and modular design. For Day-Ahead trading, the solution delivers a streamlined bidding process, detailed trade-result handling, and comprehensive safety features, making it possible to optimise all assets in the marketplace without spending time on manual processing. The fully automated Intraday Trading capability handles balance management and available capacity optimisation for all assets, round-the-clock, with highly flexible and dynamic trading strategy tools. Furthermore, the Ancillary Services capability optimises capacity in the aFRR, mFRR, and FCR markets.
Erik Forsén, Product Owner for Ancillary Services at Stockholm Exergi, commented: “To be truly effective when trading in physical marketplaces requires modern, automated trading tools. Our decision to begin operating as a balance-responsible party reinforced the need for a platform to optimise our asset fleet’s trading in multiple marketplaces. Tailored tools for bid handling and market communication convinced us that Hansen Trade was the right market solution to meet our evolving needs. Hansen also has a deep knowledge of the electricity markets and offers valuable advice on everything from strategy to operations. With Hansen Trade, we can start trading operations seamlessly and ensure that we unlock the total value potential of all our assets.”
David Castree, Chief Customer Officer at Hansen, commented: “It is clear that Stockholm Exergi are visionaries in the sector. Their transition from a conventional city-based energy provider to an active power trader, their participation in COP27, plus the announced creation – supported by the European Innovation Fund – of a carbon-capture and storage facility prove that. As such, their choice of Hansen Trade as the strategic power trading platform is all the more consequential and a genuine endorsement of Hansen’s leadership Hansen in this important space. Hansen’s power trading platform empowers several energy companies across the Nordic region, with Skelleftea Kraft, Bixia, Vantaa Energy, Tampereen Sähkölaitos, Malarenergi and Jämtkraft, to name a few. Leveraging Hansen Trade, these organisations operate with unparalleled agility in a highly dynamic market.”
Part of the Hansen Suite for Energy & Utilities, and delivered as a cloud-based SaaS solution, Hansen Trade fully meets the flexibility and scalability demands of the evolving energy trading market.
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water, and communications industries. With its award-winning software portfolio, Hansen serves customers in over 80 countries, helping them create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
Stockholm Exergi
Stockholm Exergi is Stockholm’s energy provider. Using resource-efficient solutions, Stockholm Exergi ensures that the growing Stockholm region has access to electricity, heating, cooling, and waste services. The company provides heat to more than 800,000 residents, and its 3,000-kilometre-long district heating network forms the basis for the societal benefits that Stockholm Exergi creates with its customers and partners.
For more information, visit https://www.stockholmexergi.se/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240425659483/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
